After tirzepatide was taken off the shortage list last week, I notice that there are suddenly a lot more people talking about this route. It will be interesting to see how it plays out.

Probably exceeds my comfort level, and I'm lucky enough that I can pay the $550/month for name brand if necessary. A lot of people will just have to stop, though, and deal with the consequences.